Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole

Gynecological Endocrinology

Volumn 10, Issue 5, 1996, Pages 343-348

  Lupoli, G ^a,b   Nuzzo, V ^a   Di Carlo, C ^a   Affinito, P ^a   Vollery, M ^a   Vitale, G ^a   Cascone, E ^a   Arlotta, F ^a   Nappi, C ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Parco Arcadia no8 ^*  (Italy)

Author keywords

Bisphosphonate; Bone mineral density; Hyperthyroidism; Osteocalcin; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ESTRADIOL; MEDROXYPROGESTERONE ACETATE; OSTEOCALCIN; THIAMAZOLE; THYROID HORMONE;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; THYROID HORMONE BLOOD LEVEL; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0029907386     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.3109/09513599609012821     Document Type: Article

References (38)

1. Meunier, P. J. (1995). Hyperthyroidism and osteoporosis. Ann. Endocrinol. (Paris), 56, 57-9
2. Ford, H. C., Crooke, M. J. and Murphy, C. E. (1989). Disturbances of calcium and magnesium metabolism occur in most hyperthyroid patients. Clin. Biochem., 22, 373-6
3. Ross, D. S. (1994). Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid, 4, 319-26
4. Mosekilde, L., Melsen, F., Bagger, J. P., Myhre-Jensen, O. and Sorensen, N. S. (1977). Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism. Acta Endocrinol. (Copenh.), 85, 515-25
5. Peerenboom, H., Keck, E., Kruskemper, H. L. and Strohmeyer, G. (1984). The defect of intestinal calcium transport in hyperthyroidism and its response to therapy. J. Clin. Endocrinol. Metab., 59, 936-40
6. 47Ca-kinetics: efficiency of serum bone gamma-carboxyglutamic acid-containing protein, serum alkaline phosphatase and urinary hydroxyproline excretion. J. Clin. Invest., 76, 2254-8
7. Eyre, D. R. (1992). Editorial: New markers of bone resorption. J. Clin. Endocrinol. Metab., 74, 470A-C
8. Delmas, P. D., Demiaux, B., Malaval, L., Chapuy, M. C., Edouard, C. and Meunier, P. J. (1986). Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia: comparison with bone histomorphometry. J. Clin. Invest., 77, 985-91
9. Stepan, J. J., Prest, J., Broulik, P. and Pacovsky, V. (1987). Serum osteocalcin levels and bone alkaline phosphatase isoenzyme after oophorectomy and in primary hyperparathyroidism. J. Clin. Endocrinol. Metab., 64, 1079-82
10. Merle, B. and Delmas, P. D. (1990). Normal carboxylation of circulating osteocalcin (bone GLA-protein) in Paget's disease of bone. Bone Miner., 11, 237-45
11. Garnero, P., Vassy, V., Bertholin, A., Riou, J. P. and Delmas, P. D. (1994). Markers of bone turnover in hyperthyroidism and the effects of treatment. J. Clin. Endocrinol. Metab., 78, 955-9
12. De Menis, E., Da Rin, G., Roiter, I., Legovini, P., Foscolo, G. and Conte, N. (1992). Bone turnover in overt and subclinical hyperthyroidism due to autonomous thyroid adenoma. Horm. Res., 37, 217-20
13. Diamond, T., Vine, J., Smart, R. and Butler, P. (1994). Thyrotoxic bone disease in women: a potentially reversible disorder. Ann. Intern. Med., 120, 8-11
14. Mudde, A. H., Houben, A. J. and Nieuwenhuijzen-Kruseman, A. C. (1994). Bone metabolism during antithyroid drug treatment of endogenous subclinical hyperthyroidism. Clin. Endocrinol. (Oxf.), 41, 421-4
15. Fraser, S. A., Anderson, J. B., Smith, D. A. and Wilson, G. M. (1971). Osteoporosis and fractures following thyrotoxicosis. Lancet, 1, 981-3
16. Toh, H. S., Claunch, B. C. and Brown, P. H. (1985). Effect of hyperthyroidism and its treatment on bone mineral content. Arch. Intern. Med., 145, 883-7
17. Lalau, J. D., Sebert, J. L., Marie, A., Fournier, A. and Quichaud, J. (1986). Effect of thyrotoxicosis and its treatment on mineral and bone metabolism. J. Endocrinol. Invest., 9, 491-6
18. Mundy, G. R., Shapiro, J. L., Bandelin, J. G. and Raisz, L. G. (1976). Direct stimulation of bone resorption by thyroid hormones. J. Clin. Invest., 58, 529-34
19. Lee, M. S., Kim, S. Y., Lee, M. C., Cho, B. Y. and Min, H. K. (1990). Negative correlation between the change in bone mineral density and serum osteocalcin in patients with hyperthyroidism. J. Endocrinol. Invest., 70, 766-70
20. Melsen, F. and Mosekilde, L. (1977). Morphometric and dynamic studies of bone changes in hyperthyroidism. Acta Pathol. Microbiol. Scand. [Sec. A], 85, 141-50
21. Eriksen, E. F., Mosekilde, L. and Melsen, F. (1985). Trabecular bone remodelling and bone balance in hyperthyroidism. Bone, 6, 421-8
22. Bayley, T. A., Harrison, J. E., McNeill, K. G. and Mernagh, J. R. (1980). Effect of thyrotoxicosis and its treatment on bone mineral and muscle mass. J. Clin. Endocrinol. Metab., 50, 916-22
23. Kojima, N., Sakata, S., Nakamura, S., Nagai, K. and Miura, K. (1992). Serum concentration of osteocalcin in patients with hyperthyroidism, hypothyroidism and subacute thyroiditis. J. Endocrinol. Invest., 15, 491-6
24. Lukert, B. P., Higgins, J. G. and Stoskopf, M. M. (1986). Serum osteocalcin is increased in patients with hyperthyroidism and decreased in patients receiving glucocorticoids. J. Clin. Endocrinol. Metab., 62, 1056-8
25. Riggs, B. L. and Melton, L. J., III (1986). Involutional osteoporosis. N. Engl. J. Med., 314, 1676-86
26. Aitken, J. M., Hart, D. M., Anderson, J. B., Lindsay, R. and Smith, D. A. (1973). Osteoporosis after oophorectomy for non-malignant disease. Br. Med. J., 1, 325-8
27. Kaddam, I. M., Iqbal, S. J., Holland, S., Wong, M. and Manning, D. (1994). Comparison of serum osteocalcin with total and bone specific alkaline phosphatase and urinary hydroxyproline : creatinine ratio in patients with Paget's disease of bone. Ann. Clin. Biochem., 31, 327-30
28. Legovini, P., De Menis, E., Da Rin, G., Roiter, I., Breda, F., Artuso, V., Di Virgilio, R. and Conte, N. (1994). Increased serum levels of carboxyterminal propeptide of type 1 collagen (PICP) in hyperthyroidism. Harm. Metab. Res., 26, 334-7
29. Boonekamp, P. M., Wee-Pals, L. J. A., van Wijkvan Lennep, M. M. P., Thesingh, C. W. and Bijvoet, O. L. M. (1986). Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner., 1, 27-39
30. Rodan, G. A. and Balena, R. (1993). Bisphosphonates in the treatment of metabolic bone diseases. Ann. Med., 25, 373-8
31. O'Doherty, D. P., Bickerstaff, D. R., McCloskey, E. V., Hamdy, N. A. T., Beneton, M. N. C., Harris, S., Mian, M. and Kanis, J. A. (1990). Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate. J. Bone Miner. Res., 5, 483-91
32. Reasner, C. A., Stone, M. D., Hosking, D. J., Ballah, A. and Mundy, G. R. (1993). Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J. Clin. Endocrinol. Metab., 77, 1067-71
33. Rosen, H. N., Moses, A. C., Gundherg, C., Kung, V. T., Seyedin, S. M., Chen, T., Holick, M. and Greenspan, S. L. (1993). Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans. J. Clin. Endocrinol. Metab., 77, 664-9
34. Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D., Golub, E. and Rodan, G. A. (1991). Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest., 88, 2095-105
35. Adami, S., Baroni, M. C., Broggini, M. C., Carratelli, L., Caruso, I., Gnessi, L., Laurenzi, M., Lombardi, A., Norbiato, G., Ortolani, S., Ricerca, E., Romanini, L., Subrizi, S., Weinberg, J. and Yates, A. J. (1993). Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin. Osteoporosis Int., 3, (Suppl. 3), S21-7
36. Harris, S. T., Gerts, B. J., Genant, H. K. and Chesnut, C. H., III (1993). The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodelling in early postmenopausal women. J. Clin. Endocrinol. Metab., 76, 1399-406
37. Kanis, J. A., Gertz, B. J., Singer, F. and Ortolani, S. (1995). Rationale for the use of alendronate in osteoporosis. Osteoporosis Int., 5, 1-13
38. Liberman, U. A., Weiss, S. R., Broil, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., Seeman, E., Recker, R. R., Capizzi, T., Santora, A. C., Lombardi, A., Shah, R. V., Hirsch, L. J., Karpf, D. B. (1995). Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med., 333, 1437-43